diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5494diaendo-5494Research ArticleСтатьиArticlesМесто метформина в современном лечении и профилактике сахарного диабета 2 типаThe role of metformin in the modern strategy of treatment and prevention of type 2 diabetes mellitusСмирноваОльга МихайловнаSmirnovaOlga Mikhailovnadr_smr@mail.ruФГУ Эндокринологический научный центр, МоскваEndocrinological Research Centre, Moscow201015092010133№3 (2010)8390Copyright © Смирнова О.М., 20102010Смирнова О.М.Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5494

Метформин является основным антигипергликемическим препаратом при лечении сахарного диабета 2 типа. Дается анализ механизмаего действия. Описаны кардиопротективные и антионкологические свойства. Приводятся данные многоцентровых исследований с ис-пользованием метформина.

Metformin is a major antihyperglycemic agent used for the treatment of DM2. Analysis of the mechanism of its action is presented. Cardioprotectiveand anticancer activities of metformin are discussed. Results of multicentre studied of metformin are described.

сахарный диабет 2 типаметформинлактатацидозхроническая сердечная недостаточностьантионкогенное дей- ствиеtype 2 diabetes mellitusmetforminlactacidosischronic cardiac failureantioncogenic activityReferencesMetformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 1.Metformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 1.Metformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 37.Metformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 37.Metformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 77-88.Metformin. The Gold Standard. A Scientific Handbook. / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 77-88.Muller S., Denet S., Candiloros H. Action of metformin on erythrocyte membrane fluidity in vitro and in vivo // European Jornal of Pharmacology. - 1997. - 337. - Р. 103-110.Muller S., Denet S., Candiloros H. Action of metformin on erythrocyte membrane fluidity in vitro and in vivo // European Jornal of Pharmacology. - 1997. - 337. - Р. 103-110.Jonson A.B., Webster J.M., SUM C.F. The impact of metformin therapy on hepatic glucose production and sceletal muscule glycogen synthase activity in overweight type 2 diabetes patients // Metabolism. - 1993. - 42. - Р. 1217-1222.Jonson A.B., Webster J.M., SUM C.F. The impact of metformin therapy on hepatic glucose production and sceletal muscule glycogen synthase activity in overweight type 2 diabetes patients // Metabolism. - 1993. - 42. - Р. 1217-1222.Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T. Effect of Rosiglitazone and Metformin on liver fat content, hepatic insulin resistance, insulin clearancew, and gen expression in adipose tissue in patients with type 2 diabetes / Diabetes 2004. - 53. - Р. 2169-2176.Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T. Effect of Rosiglitazone and Metformin on liver fat content, hepatic insulin resistance, insulin clearancew, and gen expression in adipose tissue in patients with type 2 diabetes / Diabetes 2004. - 53. - Р. 2169-2176.Scarpello J.H. Improving survival with metformin: the evidence base to day // Diabetes and Metabolism. - 2003. - 29. - 6S36-6S43.Scarpello J.H. Improving survival with metformin: the evidence base to day // Diabetes and Metabolism. - 2003. - 29. - 6S36-6S43.Bailey C.J., Howlett H.C.S. Defining patient populations not indicated for metformin. // Metformin. The Gold Standard. A Scientific Handbook / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 193-198.Bailey C.J., Howlett H.C.S. Defining patient populations not indicated for metformin. // Metformin. The Gold Standard. A Scientific Handbook / Ed. Bailey C.J., Campbell J.W., Chan J.C.N. Wiley. - 2007. - P. 193-198.Emsley-Smith A.M., Boyle D.I., Evance J.M., Sullivan F., Morris A.D. Contraindication to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing quidelines // Diabetic Medicine. - 2003. - 18. - Р. 483-488.Emsley-Smith A.M., Boyle D.I., Evance J.M., Sullivan F., Morris A.D. Contraindication to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing quidelines // Diabetic Medicine. - 2003. - 18. - Р. 483-488.Stacpoole P.W., Wright E.C., Baumgarten T.G. Natural history and course of acquired lactic acidosis in adult. DCA-Lactic Acidosis Study Groop // The Am. Jornal of Medicine. - 1992. - 97. - Р. 47-54.Stacpoole P.W., Wright E.C., Baumgarten T.G. Natural history and course of acquired lactic acidosis in adult. DCA-Lactic Acidosis Study Groop // The Am. Jornal of Medicine. - 1992. - 97. - Р. 47-54.Eurich D.T., Majumdar S.R., Mc Alister F.A., Tsuyuki R.T., Johanson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure // Diabetes care. - 2005. - 28. - Р. 2345- 2351.Eurich D.T., Majumdar S.R., Mc Alister F.A., Tsuyuki R.T., Johanson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure // Diabetes care. - 2005. - 28. - Р. 2345- 2351.Mc Donald A., Eurich D.T., Mayumidar S.R. Treatment of type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From UK General Practice Research Datebase // Diabetes Care. - 2010. - 33. - Р. 1210-1219.Mc Donald A., Eurich D.T., Mayumidar S.R. Treatment of type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From UK General Practice Research Datebase // Diabetes Care. - 2010. - 33. - Р. 1210-1219.Bowker S.L., Veugelers P., Majumdar S.R., Jonson J.A. Increased Cancer- Related Mortalitt for Patients With Type 2 Diabetes Who Use Sulfanilureas or Insulin // Diabetes Care. - 2006. - 29. - Р. 254-258.Bowker S.L., Veugelers P., Majumdar S.R., Jonson J.A. Increased Cancer- Related Mortalitt for Patients With Type 2 Diabetes Who Use Sulfanilureas or Insulin // Diabetes Care. - 2006. - 29. - Р. 254-258.Currie C.J., Pool C.D., Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes // Diabetology. DOI: 10. 1007/s00125-009-1440-6.Currie C.J., Pool C.D., Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes // Diabetology. DOI: 10. 1007/s00125-009-1440-6.Landman G.W.G., Kleefstra N., Van Haleren K.J.J. Metformin associated with Lower Cancer Mortality in Type 2 Diabetes // Diabetes Care. - 2010. - 33. - Р. 322-326.Landman G.W.G., Kleefstra N., Van Haleren K.J.J. Metformin associated with Lower Cancer Mortality in Type 2 Diabetes // Diabetes Care. - 2010. - 33. - Р. 322-326.Бернштейн Л.М. Гиполипидемические и антидиабетические препа- раты как средство предупреждения и терапии злокачественных опу- холей: клинические данные. НИИ онкологии им. проф. Н.Н. Петрова МЗ РФ, Санкт-Петербург // Сборник тезисов VIII Российского онкологического конгресса. - М., 2004. - С. 106-108 .Бернштейн Л.М. Гиполипидемические и антидиабетические препа- раты как средство предупреждения и терапии злокачественных опу- холей: клинические данные. НИИ онкологии им. проф. Н.Н. Петрова МЗ РФ, Санкт-Петербург // Сборник тезисов VIII Российского онкологического конгресса. - М., 2004. - С. 106-108 .

The authors declare that there are no conflicts of interest present.